RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients–a short report

Abstract

Purpose RRM1 is the large subunit of ribonucleotide reductase (RNR), which catalyzes the rate-limiting step in the production of deoxyribonucleotides (dNTPs) and is essential for DNA synthesis and repair. Through a meta-analysis of observational studies, we evaluated whether RRM1 expression levels are associated with the clinical outcome of gemcitabine-containing treatment regimens in patients with advanced non-small cell lung cancer (NSCLC). Methods A literature search was conducted using the PubMed, Embase, Web of Science, Wanfang and Chinese National Knowledge Infrastructure databases from inception to September 2014. A meta-analysis was conducted to pool eligible studies, and pooled analyses were performed using fixed effects models. Results A total of 12 studies encompassing 593 NSCLC patients met our search criteria and were, therefore, included. Pooled analyses revealed that patients with low/negative RRM1 expression levels exhibited significantly higher response rates (OR: 0.35, 95 % CI 0.24-0.51) and better survival rates (OR: 0.41, 95 % CI 0.23-0.75) than those with high/ positive RRM1 expression levels. Subgroup analyses did not reveal any significant heterogeneity in outcome regarding the RRM1 assessment methods used or the ethnicities of patient populations studied. Conclusions The meta-analysis reported here indicates that RRM1 expression is associated with the response rate and overall survival rate of advanced NSCLC patients treated with gemcitabine-based chemotherapy. Additional phase III randomized trials are required to confirm our current findings.

Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers

“…Non-small cell lung cancers (NSCLCs), which represent 85 % of all human lung cancers, frequently exhibit multi-drug resistance (MDR), which seriously hampers the treatment of this disease [1][2][3]. Doxorubicin (DOX) is a potent anti-cancer drug belonging to the anthracycline family.…”

Nitric oxide increases the migratory activity of non-small cell lung cancer cells via AKT-mediated integrin αv and β1 upregulation

“…Since metastasis is one of the most crucial factors determining the survival of cancer patients, ample attempts have been made to identify key molecular mediators that control metastasis. Nonsmall cell lung cancer (NSCLC) is a highly metastatic malignancy, and the disease is estimated to be the leading cause of cancer-related death [4][5][6][7][8]. The endogenous gas nitric oxide (NO) is known to play a role in the progression of different types of cancer [9] and it has been found that the expression of several forms of NO synthases (NOSs) is strongly upregulated in, among others, NSCLC cells [10].…”

In vitro evolution and whole genome analysis to study chemotherapy drug resistance in haploid human cells

“…RRM1 is the largest catalytic subunit of ribonucleotide reductase, a key enzyme catalyzing the transformation of ribonucleotide diphosphates to deoxyribonucleoside diphosphates that are required for DNA synthesis and repair, and GEM is known to inhibit DNA polymerase by inhibiting RRM1 (45). Furthermore, overexpression of RRM1 is associated with poorer prognosis after gemcitabine treatment in non-small cell lung cancer (46) and in bladder cancer (47).…”